Etiology of Eczema Herpeticum (EH)

Inclusion Criteria:

1. Must be a participant already enrolled in the ADRN Registry and provided DNA (ClinicalTrials.gov ID: NCT01494142);
2. Participant and/or parent guardian must be able to understand and provide informedconsent;
3. A history of Atopic Dermatitis (AD) with a history of eczema herpeticum (ADEH+), asdiagnosed using the Atopic Dermatitis Research Network (ADRN) Standard DiagnosticCriteria, with ≥3 episodes of Eczema Herpeticum (EH) OR A history of AD without a history of eczema herpeticum (ADEH-), as diagnosed using theADRN Standard Diagnostic Criteria, and no immediate family members (mother, father,full siblings, half-siblings, offspring, aunts, uncles, cousins, or grandparents) witha history of EH OR Non-atopic as diagnosed using the ADRN Standard Diagnostic Criteria.
4. Anti-Herpes Simplex Virus (HSV)-1 or Anti-HSV-2 Immunoglobulin G (IgG) seropositive.

Exclusion Criteria:

1. Inability or unwillingness of a participant and/or parent guardian to give writteninformed consent or comply with study protocol;
2. Pregnant or lactating women;
3. Known or suspected immunosuppression;
4. Severe concomitant illness(es);
5. History of keloid formation (adults only);
6. History of lidocaine or Novocain allergy (adults only);
7. History of serious life-threatening reaction to latex, tape, or adhesives;
8. Past or current medical problems or findings from physical examination or laboratorytesting that are not listed above, which, in the opinion of the investigator, may poseadditional risks from participation in the study, may interfere with the participant'sability to comply with study requirements or that may impact the quality orinterpretation of the data obtained from the study.
9. Use of biologics within 5 half-lives (if known) or 16 weeks of the Screening Visit;
10. Use of an investigational drug within 5 half-lives (if known) or 8 weeks of theScreening Visit.